Clinical Trial Update: A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating Copanlisib in combination with Degarelix for prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Copanlisib (copanlisib)
• degarelix (degarelix)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: WITHDRAWN